There’s a new vaccine in town.
Novavax makes a vaccine using different technology than the three current vaccines in use, using small ‘laboratory-built pieces of the coronavirus to stimulate immunity.’
Vaccine advisers to the US Food and Drug Administration decided Tuesday that authorizing Novavax’s new vaccine is ‘beneficial’ and recommended emergency use authorization.
If the full FDA gives the vaccine the green light, it will become the fourth Covid-19 vaccine authorized in the United States.
As with Pfizer/BioNTech and Moderna, it would be a two-dose series.
Novavax’s vaccine is made using small laboratory-built pieces of the coronavirus to stimulate immunity. This protein-based approach is a more traditional one for vaccine development than the mRNA vaccines from Pfizer/BioNTech and Moderna.
It is already in use in the European Union, the United Kingdom, Canada, South Korea, Australia, India, the Philippines and New Zealand, among other countries.